Knockdown of NANOG enhances chemosensitivity of liver cancer cells to doxorubicin by reducing MDR1 expression

Zhou,Jia-Jia; Deng,Xiao-Geng; He,Xiao-Yu; Zhou,Yu; Yu,Min; Gao,Wen-Chao; Zeng,Bing; Zhou,Quan-Bo; Li,Zhi-Hua; Chen,Ru-Fu

doi:10.3892/ijo.2014.2347

Knockdown of NANOG enhances chemosensitivity of liver cancer cells to doxorubicin by reducing MDR1 expression

Authors:
- Jia-Jia Zhou
- Xiao-Geng Deng
- Xiao-Yu He
- Yu Zhou
- Min Yu
- Wen-Chao Gao
- Bing Zeng
- Quan-Bo Zhou
- Zhi-Hua Li
- Ru-Fu Chen
View Affiliations

Affiliations: Department of Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China, Laboratory of Biomechanics and Physiology, Guangdong Provincial Institute of Sports Science, Guangzhou, Guangdong, P.R. China, Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P.R. China
Published online on: March 19, 2014 https://doi.org/10.3892/ijo.2014.2347
Pages: 2034-2040

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multidrug resistance (MDR) is one of the major reasons for the failure of liver cancer chemotherapy, and its suppression may increase the efficacy of chemotherapy. NANOG plays a key role in the regulation of embryonic stem cell self-renewal and pluripotency. Recent studies reported that NANOG was abnormally expressed in several types of tumors, indicating that NANOG is related to tumor development. However, the correlation between NANOG and liver cancer chemoresistance remains uncertain. In this study, RNA interfere technology was employed to knock down NANOG expression in HepG2 human liver cancer cells. We found that the knockdown of NANOG expression in NANOG siRNA-transfected HepG2 cells resulted in decreased colony formation rate and cell migration compared to control HepG2 cells. In addition, HepG2 cells were treated with doxorubicin to evaluate the chemosensitivity to doxorubicin. We found that the doxorubicin sensitivity of HepG2 cells was increased with downregulation of NANOG expression. The expression of MDR1 at both mRNA and protein levels was decreased in HepG2 cells when NANOG was knocked down. These findings suggest that the knockdown of NANOG in HepG2 human cells resulted in decreased MDR1 expression and increased doxorubicin sensitivity, and NANOG could be used as a novel potential therapeutic target to reverse multidrug resistance of liver cancer.

View Figures

View References

1.	Okuda K: Hepatocellular carcinoma. J Hepatol. 32:225–237. 2000. View Article : Google Scholar
2.	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
3.	Lee JH, Chung YH, Kim JA, et al: Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer. 119:136–142. 2013. View Article : Google Scholar : PubMed/NCBI
4.	Sauer G, Kafka A, Grundmann R, Kreienberg R, Zeillinger R and Deissler H: Basal expression of the multidrug resistance gene 1 (MDR-1) is associated with the TT genotype at the polymorphic site C3435T in mammary and ovarian carcinoma cell lines. Cancer Lett. 185:79–85. 2002. View Article : Google Scholar : PubMed/NCBI
5.	Ling V: Multidrug resistance and P-glycoprotein expression. Ann NY Acad Sci. 507:7–8. 1987. View Article : Google Scholar : PubMed/NCBI
6.	Roninson IB, Chin JE, Choi KG, et al: Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA. 83:4538–4542. 1986. View Article : Google Scholar : PubMed/NCBI
7.	Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S and Smith A: Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 113:643–655. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Mitsui K, Tokuzawa Y, Itoh H, et al: The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 113:631–642. 2003. View Article : Google Scholar : PubMed/NCBI
9.	Freberg CT, Dahl JA, Timoskainen S and Collas P: Epigenetic reprogramming of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract. Mol Biol Cell. 18:1543–1553. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A and Weinberg RA: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 40:499–507. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Gu G, Yuan J, Wills M and Kasper S: Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 67:4807–4815. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Zbinden M, Duquet A, Lorente-Trigos A, Ngwabyt SN, Borges I and Ruiz i Altaba A: NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J. 29:2659–2674. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Seigel GM, Hackam AS, Ganguly A, Mandell LM and Gonzalez-Fernandez F: Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis. 13:823–832. 2007.PubMed/NCBI
14.	Meng HM, Zheng P, Wang XY, et al: Overexpression of nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther. 9:295–302. 2010. View Article : Google Scholar : PubMed/NCBI
15.	Jeter CR, Badeaux M, Choy G, et al: Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells. 27:993–1005. 2009. View Article : Google Scholar : PubMed/NCBI
16.	Jeter CR, Liu B, Liu X, et al: NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene. 30:3833–3845. 2011. View Article : Google Scholar : PubMed/NCBI
17.	Du Y, Shi L, Wang T, Liu Z and Wang Z: Nanog siRNA plus Cisplatin may enhance the sensitivity of chemotherapy in esophageal cancer. J Cancer Res Clin Oncol. 138:1759–1767. 2012. View Article : Google Scholar : PubMed/NCBI
18.	Dalerba P, Cho RW and Clarke MF: Cancer stem cells: models and concepts. Annu Rev Med. 58:267–284. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Dalerba P and Clarke MF: Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell. 1:241–242. 2007. View Article : Google Scholar : PubMed/NCBI
20.	Yu F, Yao H, Zhu P, et al: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 131:1109–1123. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Xu XL, Xing BC, Han HB, et al: The properties of tumor-initiating cells from a hepatocellular carcinoma patient’s primary and recurrent tumor. Carcinogenesis. 31:167–174. 2010.
22.	Al-Hajj M: Cancer stem cells and oncology therapeutics. Curr Opin Oncol. 19:61–64. 2007.PubMed/NCBI
23.	Boyer LA, Lee TI, Cole MF, et al: Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 122:947–956. 2005. View Article : Google Scholar : PubMed/NCBI
24.	Tang Y, Kitisin K, Jogunoori W, et al: Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci USA. 105:2445–2450. 2008. View Article : Google Scholar : PubMed/NCBI
25.	Lin YL, Han ZB, Xiong FY, et al: Malignant transformation of 293 cells induced by ectopic expression of human Nanog. Mol Cell Biochem. 351:109–116. 2011. View Article : Google Scholar
26.	Lee TK, Castilho A, Cheung VC, Tang KH, Ma S and Ng IO: CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell. 9:50–63. 2011.
27.	Shan J, Shen J, Liu L, et al: Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology. 56:1004–1014. 2012. View Article : Google Scholar : PubMed/NCBI
28.	Xin H, Kong Y, Jiang X, et al: Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell properties. J Pharmacol Sci. 122:299–304. 2013. View Article : Google Scholar : PubMed/NCBI
29.	Pérez-Tomás R: Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 13:1859–1876. 2006.PubMed/NCBI
30.	Goda K, Bacsó Z and Szabó G: Multidrug resistance through the spectacle of P-glycoprotein. Curr Cancer Drug Targets. 9:281–297. 2009. View Article : Google Scholar : PubMed/NCBI
31.	Lage H: MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr Drug Targets. 7:813–821. 2006. View Article : Google Scholar
32.	He Y, Bi Y, Hua Y, et al: Ultrasound microbubble-mediated delivery of the siRNAs targeting MDR1 reduces drug resistance of yolk sac carcinoma L2 cells. J Exp Clin Cancer Res. 30:1042011. View Article : Google Scholar : PubMed/NCBI